JOIN US »
4th Advances in Circulating Tumor Cells (ACTC) Conference in Greece
Learn How New CTC Assays Can Play an Important Role in Lung and Bladder Cancer Management
Learn More About The Next Generation of Single-Cell Technology. Please join us as we partner with IncellDx at the 4th ACTC meeting in Corfu, Greece, on October 2–5, 2019 (www.actc2019.org). This year’s conference focuses on late-breaking news in CTCs, ctDNA, circulating miRNAs and extracellular vesicles technologies and their clinical applications. Our team will be there to schedule one-to-one office hours on the 3rd and 4th of October.
The Genesis System for CTC Enumeration. The lack of reproducibility and sensitivity with legacy technologies has limited the clinical adoption of circulating tumor cells (CTCs) for cancer monitoring. The Genesis System was developed by Celsee to address the shortcomings of single-cell analysis including CTC isolation and enumeration. Learn more »
Our Partnership With IncellDx. Celsee and IncellDx have partnered to provide a comprehensive suite of products to rapidly and conveniently evaluate your cancer patients from Primary Tumor to Monitoring Circulating Tumor Cells (CTCs). See how these new tools for screening primary lung and bladder tumors can monitor with ultra-sensitive CTC assays.
Dates & Booth Information
October 2nd – 5th, 2019